Revive Therapeutics held its annual shareholder meeting

Revive Therapeutics Ltd., a specialty life sciences company based in Toronto, has shared results from its annual shareholder meeting held on March 18, 2025. During the meeting, shareholders elected new members to the board of directors. The company's board also decided not to move forward with a proposal to change the articles of incorporation to consolidate its common shares. This decision was influenced by feedback from shareholders. Revive Therapeutics is focused on developing treatments for infectious diseases and rare disorders. The company is particularly working on drug developments that benefit from various FDA regulatory incentives, including Emergency Use Authorization and Breakthrough Therapy designations. Currently, Revive is investigating Bucillamine as a potential treatment for nerve agent exposure and long COVID. Additionally, the company is progressing with programs involving Psilocybin-based therapies. For further inquiries, Michael Frank, the Chief Executive Officer, is available for contact.